Granules India Limited (GRANULES) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

Granules India enters Q1 FY27 results following a year of portfolio transformation and a sharp reduction in net debt. Investors will be looking for updates on the Gagillapur facility's regulatory status and whether the company can maintain its margin trajectory amidst rising input costs.

Granules India Limited Q1 Results Date and Time

The board meeting is scheduled for July 21, 2026, to consider the financial results.

The earnings call is scheduled for July 21, 2026, at 5 PM IST.

What to expect from Granules India Limited's Q1 FY27 results

Granules India is expected to report strong year-over-year revenue growth in Q1 FY27, supported by a weaker rupee and the full-quarter consolidation of Senn Chemicals AG. While the company's formulations business aims for double-digit growth in FY27, gross margins are likely to face pressure from a 200-300% surge in certain chemical feedstock costs and limited price pass-through on essential medicines. EBITDA margins are expected to moderate from the Q4 FY26 peak of 23.9% toward the 22-23% range as the company absorbs annual salary increments and elevated freight expenses. Management's ability to maintain sustainable profitability in the Peptide CDMO segment, which generated Rs. 70 Cr in revenue in Q4, remains a key performance indicator. The balance sheet will be monitored for a sequential rise in net debt from the March-end level of Rs. 402.10 Cr, consistent with typical Q1 working capital cycles and planned FY27 capex of Rs. 600 Cr.

Key Things To Watch

Gagillapur re-inspection update: The resolution of the warning letter remains the most critical regulatory catalyst for the company.

• Status of any FDA communication or scheduling for re-inspection following the completion of remediation in March 2026
• Impact of ongoing capacity constraints on new product approvals and revenue realization

Margin trajectory amid cost escalation: Management has stepped back from the 24-25% EBITDA margin target due to market uncertainty.

• Ability to pass through raw material, packaging, and freight cost escalations
• Sustainability of gross margins relative to the Q4 FY26 level of 65.7%

Peptide CDMO scale-up: The segment achieved EBITDA breakeven in Q4 FY26 and is a key strategic growth engine.

• Maintenance of positive EBITDA contribution in Q1 FY27
• Progress on the India-based peptide manufacturing facility expected to be operational by the end of FY27

GLS (Genome Valley) commercialization: The facility represents a 40% capacity increase over the Gagillapur site.

• Revenue contribution and volume of Rx product launches in Q1
• Status of European regulatory approvals for the site

Performance vs Guidance Tracking: Monitoring progress against directional targets for FY27.

• Base business double-digit growth — tracking Q1 performance against FY27 outlook
• Net debt management — monitoring for a slight increase from Rs. 402 Cr in line with capex plans